Norvēģija -
norvēģu -
Statens legemiddelverk
targiniq 20 mg / 10 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 20 mg / 10 mg
Norvēģija -
norvēģu -
Statens legemiddelverk
targiniq 30 mg / 15 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 30 mg / 15 mg
Norvēģija -
norvēģu -
Statens legemiddelverk
targiniq 40 mg / 20 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 40 mg / 20 mg
Norvēģija -
norvēģu -
Statens legemiddelverk
voltaren ophtha abak 1 mg/ ml
laboratoires théa - cedex 2 - diklofenaknatrium - Øyedråper, oppløsning - 1 mg/ ml
Norvēģija -
norvēģu -
Statens legemiddelverk
tresuvi 10 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 10 mg/ ml
Norvēģija -
norvēģu -
Statens legemiddelverk
tresuvi 1 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 1 mg/ ml
Norvēģija -
norvēģu -
Statens legemiddelverk
tresuvi 2.5 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 2.5 mg/ ml
Norvēģija -
norvēģu -
Statens legemiddelverk
tresuvi 5 mg/ ml
amomed pharma gmbh - treprostinilnatrium - infusjonsvæske, oppløsning - 5 mg/ ml
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
drovelis
gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - sex hormoner og modulatorer av genital systemet, - oral contraceptive.
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - sex hormoner og modulatorer av genital systemet, - oral prevensjon. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.